Antipsychotics and QT prolongation

被引:115
作者
Taylor, DM
机构
[1] S London & Maudsley NHS Trust, Maudsley Hosp, Dept Pharm, London SE5 8AZ, England
[2] Inst Psychiat, London, England
关键词
antipsychotics; QT interval; dysrhythmia; mortality;
D O I
10.1034/j.1600-0447.2003.02078.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To evaluate literature relating to cardiac QT prolongation and the use of antipsychotic drugs. Method: Literature searches of EMBASE, Medline, PsychLIT were performed in December 2001 and reference sections of retrieved papers scrutinized for further relevant reports. Results: The Cardiac QTc interval is difficult to measure precisely or accurately but appears to be a useful predictor of risk of dysrhythmia (specifically torsade de pointes) and sudden death. It is less clear that drug-induced QTc prolongation gives rise to similar risks but data are emerging, linking antipsychotic use to increased cardiac mortality. Many antipsychotics have been clearly associated with QTc prolongation. Methodological considerations arguably preclude assuming that any antipsychotic is free of the risk of QTc prolongation and dysrhythmia. Conclusion: Available data do not allow assessment of relative or absolute risk of dysrhythmia or sudden death engendered by antipsychotics but caution is advised. Risk of dysrhythmia can very probably be reduced by careful prescribing of antipsychotics in low doses in simple drug regimens which avoid metabolic interactions. Electrocardiographic monitoring may also help to reduce risk but review by specialist cardiologist may be necessary.
引用
收藏
页码:85 / 95
页数:11
相关论文
共 138 条
[21]   Overdose profiles of new antipsychotic agents [J].
Capel, MM ;
Colbridge, MG ;
Henry, JA .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2000, 3 (01) :51-54
[22]   Association of autonomic dysfunction and clozapine - Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication [J].
Cohen, H ;
Loewenthal, U ;
Matar, M ;
Kotler, M .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 179 :167-171
[23]  
*COMM SAF MED, 2001, CURRENT PROBLEMS PHA, V27, P4
[24]   A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder [J].
Conley, RR ;
Mahmoud, R .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (05) :765-774
[25]  
Conley RR, 2000, J CLIN PSYCHIAT, V61, P20
[26]   A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia [J].
Cooper, SJ ;
Tweed, J ;
Raniwalla, J ;
Butler, A ;
Welch, C .
ACTA PSYCHIATRICA SCANDINAVICA, 2000, 101 (03) :218-225
[27]   Amisulpride - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia [J].
Coukell, AJ ;
Spencer, CM ;
Benfield, P .
CNS DRUGS, 1996, 6 (03) :237-256
[28]   Safety of amisulpride (Solian®):: a review of 11 clinical studies [J].
Coulouvrat, C ;
Dondey-Nouvel, L .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (04) :209-218
[29]  
Cozza K. L., 2001, CYTOCHROME P450 SYST
[30]  
Czekalla J, 2001, J CLIN PSYCHIAT, V62, P35